Department of Pediatrics, Fatih University Medical School, Ankara, Turkey.
Int Urol Nephrol. 2009 Dec;41(4):953-7. doi: 10.1007/s11255-008-9445-5. Epub 2008 Aug 14.
In patients with suspected urinary tract infection (UTI), antibiotic treatment is usually started empirically, before urine culture results are available. Unfortunately, antibiotic resistance has become an increasingly pressing clinical issue in many countries. The objective of this study was to assess the changing susceptibility of urinary pathogens to commonly used antimicrobials in a six-year period to evaluate the options for empirical antibiotic therapy in children with community acquired UTI.
A retrospective analysis of data from all pediatric urine samples processed at Fatih University Medical School microbiology laboratory was undertaken for a period of six years (January 2000-December 2006).
A total of 767 urinary pathogens were isolated from 767 episodes of UTI in 698 patients. The most common causative agent was Escherichia coli (E. coli) followed by Klebsiella spp. and others. In 2000 almost 60% of the E. coli isolates were susceptible to ampicillin (AMP), more than 40% to Co-trimoxazole (SXT), more than 80% to gentamicin (GN), more than 90% to cefuroxime (CXM) and amikacin (AN), and more than 60% to piperacillin (PIP). By 2006 more than 70% were resistant to AMP and more than 50% were resistant to PIP. In 2000 CIP (2.7% resistant isolates) and CXM (3.4% resistant isolates) were the most active agents against Klebsiella spp.; and none of the isolates was found to be resistant to imipenem (IMP). In 2006 GN (2.7% resistant isolates), CIP (3.5% resistant isolates), CXM (2.7% resistant isolates), and AN (8.9% resistant isolates) were the most active agents against these species and still no resistance to IMP was found. For E. Coli the increase in resistance to AMP, CTX, IMP, and PIP was statistically significant (P < 0.05). For Klebsiella spp. the increase in resistance to AMP and CXM was statistically significant (P < 0.05).
Empirical antibiotic selection should be based on knowledge of the local prevalence of bacterial organisms and antibiotic sensitivities, because resistance patterns may vary in different regions.
在疑似尿路感染(UTI)患者中,在获得尿液培养结果之前,通常会根据经验开始使用抗生素治疗。不幸的是,抗生素耐药性已成为许多国家日益紧迫的临床问题。本研究的目的是评估在六年期间尿病原体对常用抗菌药物的敏感性变化,以评估社区获得性 UTI 患儿经验性抗生素治疗的选择。
对 Fatih 大学医学院微生物实验室六年来(2000 年 1 月至 2006 年 12 月)处理的所有儿科尿液样本进行了回顾性分析。
767 名患者的 767 例 UTI 中有 767 株尿病原体分离株。最常见的病原体是大肠埃希菌(E. coli),其次是克雷伯菌属和其他菌属。2000 年,近 60%的大肠杆菌分离株对氨苄西林(AMP)敏感,超过 40%对复方磺胺甲噁唑(SXT)敏感,超过 80%对庆大霉素(GN)敏感,超过 90%对头孢呋辛(CXM)和阿米卡星(AN)敏感,超过 60%对哌拉西林(PIP)敏感。到 2006 年,超过 70%的 AMP 耐药,超过 50%的 PIP 耐药。2000 年,CIP(2.7%耐药分离株)和 CXM(3.4%耐药分离株)是对克雷伯菌属最有效的药物;没有分离株对亚胺培南(IMP)耐药。2006 年,GN(2.7%耐药分离株)、CIP(3.5%耐药分离株)、CXM(2.7%耐药分离株)和 AN(8.9%耐药分离株)是对这些物种最有效的药物,仍然没有发现对 IMP 的耐药性。对于大肠杆菌,对 AMP、CTX、IMP 和 PIP 的耐药性增加具有统计学意义(P<0.05)。对于克雷伯菌属,对 AMP 和 CXM 的耐药性增加具有统计学意义(P<0.05)。
经验性抗生素选择应基于对当地细菌病原体和抗生素敏感性的了解,因为耐药模式可能因地区而异。